Related Experiment Video

Updated: Jul 15, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an

Hiroshi Tanaka1, Koji Tsugawa, Eishin Oki

  • 1Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, 036-8562, Japan. hirotana@cc.hirosaki-u.ac.jp

Clinical Rheumatology
|May 8, 2007
PubMed

Insights

This study shows that mizoribine (MZR) pulse therapy combined with prednisolone (PDN) effectively treats pediatric systemic lupus erythematosus (SLE), achieving complete response in most patients with lupus nephritis.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Nephrology

Background:

  • Pediatric-onset systemic lupus erythematosus (SLE) is a chronic autoimmune disease requiring effective induction therapy.
  • Lupus nephritis, a severe complication of SLE, necessitates prompt and effective treatment to prevent renal damage.
  • Current treatment protocols for pediatric SLE induction therapy are being evaluated for efficacy and safety.

Purpose of the Study:

  • To evaluate the preliminary efficacy and safety of an intermittent mizoribine (MZR) pulse protocol combined with prednisolone (PDN) for induction therapy in newly diagnosed pediatric SLE patients.
  • To assess renal response and serologic lupus activity during MZR and PDN treatment.
  • To determine the rate of SLE flares during the treatment period.

Main Methods:

  • An open-label trial involving five consecutive pediatric SLE patients with biopsy-proven lupus nephritis.
  • Patients received prednisolone (PDN) and mizoribine (MZR) intermittent pulse therapy (10 mg/kg for 2 days/week for 12 months).
  • Prospective data collection on renal response, serologic lupus activity, and SLE flares.

Main Results:

  • All patients showed significant improvement in renal and serologic parameters compared to baseline after 12 months of therapy.
  • Complete response was achieved in 4 out of 5 patients, with one patient showing poor drug compliance.
  • Histologic improvement was noted in two patients with severe lupus nephritis, and no serious adverse effects were observed.

Conclusions:

  • The MZR pulse protocol combined with PDN appears to be a promising induction therapy for selected young patients with SLE and lupus nephritis.
  • The treatment demonstrated significant efficacy in improving renal and serologic markers of disease activity.
  • Further research with larger patient cohorts is warranted to confirm long-term efficacy and safety.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...